MRNA shares surged after Moderna and Merck’s personalized cancer vaccine met key Phase 3 melanoma endpoints with no new safety concerns.
MRNA Stock Doubles After Moderna-Merck Cancer Vaccine Succeeds in Phase 3 Trial
其他语言标题
- 한국어Moderna-머크 암 백신이 3상 임상시험에서 성공한 후 MRNA 주가 두 배 급등